NEW YORK (GenomeWeb News) – HTG Molecular Diagnostics today said that it will collaborate with Sanofi US on identifying biomarkers that could become a molecular companion diagnostic test.
The potential test would identify patients most likely to respond to an investigational drug being developed by Sanofi.
HTG Molecular, a privately-held, Tucson, Ariz.-based firm, will use its qNPA technology to measure mRNA and/or miRNA expression in formalin fixed paraffin embedded tumor samples. The technology, according to the firm, enables physicians to verify the presence of certain biomarkers relevant to patient selection and therapy.
Financial and other terms of the alliance were not disclosed.